Anika Therapeutics (NASDAQ: ANIK) reported Q2 EPS of $0.06, $0.38 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $44.3 million versus the consensus estimate of $40.37 million.

GUIDANCE:

Anika Therapeutics sees FY2023 revenue of $159.5-163 million, versus the consensus of $161.9 million.

For earnings history and earnings-related data on Anika Therapeutics (ANIK) click here.